Roberta Ismael Lacerda Machado

Dr. Roberta Ismael Lacerda Machado


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Genes
Verified
Journal Article
Open access
PDF file
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
PSPaulo de Lima Serrano
Paulo de Lima Serrano
Igor Braga FariasIgor Braga Farias
Igor Braga Farias
Roberta Ismael Lacerda MachadoRoberta Ismael Lacerda Machado
Roberta Ismael Lacerda Machado
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
Acary Souza Bulle OliveiraAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
Juvenile Amyotrophic Lateral Sclerosis is a genetically heterogeneous neurodegenerative disorder, which is frequently misdiagnosed due to low clinical suspicion and little knowledge about disease characteristics. More than 20 different genetic loci have been associated with both sporadic and familial juvenile Amyotrophic Lateral Sclerosis. Currently, almost 40% of cases have an identifiable monogenic basis; type 6, associated with FUS gene variants, is the most prevalent globally. Despite several upper motor neuron-dominant forms being generally associated with long-standing motor symptoms and slowly progressive course, certain subtypes with lower motor neuron-dominant features and early bulbar compromise lead to rapidly progressive motor handicap. For some monogenic forms, there is a well-established genotypic-phenotypic correlation. There are no specific biochemical and neuroimaging biomarkers for the diagnosis of juvenile Amyotrophic Lateral Sclerosis. There are several inherited neurodegenerative and neurometabolic disorders which can lead to the signs of motor neuron impairment. This review emphasizes the importance of high clinical suspicion, assessment, and proper diagnostic work-up for juvenile Amyotrophic Lateral Sclerosis.

5 February 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
PSPaulo de Lima Serrano
Paulo de Lima Serrano
JBJoão Paulo Barile
João Paulo Barile
DSDaniel Seneor
Daniel Seneor
PMPatrícia Marques Mendes
Patrícia Marques Mendes
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Background: Acute hepatic porphyrias (AHPs) represent inherited metabolic disorders of the heme biosynthesis pathway, leading to neurological and systemic impairment. Despite the presence of well-recognized chronic symptoms and signs, acute neurological, both neuromuscular and central neurological complications pose a significant challenge in clinical practice, with a potential risk of greater severity and mortality during acute decompensation episodes of AHPs. Care related to the prescription of medications, considering the risk of porphyrinogenicity, is a major and recurring concern in the acute and chronic management of AHP patients. Infectious clinical complications are significant issues in both outpatient and hospital settings for patients with AHPs. It is crucial to identify therapeutic regimens with the best safety and efficacy profiles for treating such infectious complications in AHP patients. The scarcity of structured knowledge available in guidelines and recommendations often leads to the use of therapeutic options with higher potential risks in treating patients with AHPs. Objectives: This review article aims to provide practical recommendations for managing the most significant infectious complications in clinical practice, with a focus on their impact on the clinical care of patients with AHPs.

2 May 2022 in Journal of Pediatric Genetics
Verified
Journal Article
Closed access
PDF file
Roberta Ismael Lacerda MachadoRoberta Ismael Lacerda Machado
Roberta Ismael Lacerda Machado
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
IFIgor Braga Farias
Igor Braga Farias
BBBruno de Mattos Lombardi Badia
Bruno de Mattos Lombardi Badia
JFJosé Marcos Vieira de Albuquerque Filho
José Marcos Vieira de Albuquerque Filho
AOAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
Charcot–Marie–Tooth's disease (CMT) represents the most common inherited neuropathy. Most patients are diagnosed during late stages of disease course during adulthood. We performed a review of clinical, neurophysiological, and genetic diagnoses of 32 patients with genetically defined childhood-onset demyelinating CMT under clinical follow-up in a Brazilian Center for Neuromuscular Diseases from January 2015 to December 2019. The current mean age was 33.1 ± 18.3 years (ranging from 7 to 71 years) and mean age at defined genetic diagnosis was 36.1 ± 18.3 years. The mean age at onset was 6.1 ± 4.4 years. The most common initial complaint was bilateral pes cavus. The genetic basis included PMP22 duplication (CMT1A) (n = 18), GJB1 (CMTX1) (n = 5), MPZ (CMT1B) (n = 3), FIG4 (CMT4J) (n = 3), SH3TC2 (CMT4C) (n = 1), PLEKHG5 (CMTRIC) (n = 1), and PRX (CMT4F) (n = 1). Almost all patients (n = 31) presented with moderate or severe compromise in the CMT neuropathy score 2 with the highest values observed in CMT1B. Medical history disclosed obstructive sleep apnea (n = 5), aseptic meningitis (n = 1/MPZ), akinetic-rigid parkinsonism (n = 1/FIG4), and overlapping chronic inflammatory demyelinating polyneuropathy (n = 1/MPZ). Motor conduction block was detected in three individuals (PMP22, FIG4, MPZ). Acute denervation occurred in seven patients. Nonuniform demyelinating patterns were seen in four individuals (two CMT1A, one CMT1B, and one CMTX1). Abnormal cerebral white matter findings were detected in CMT1A and CMTX1, while hypertrophic roots were seen in CMT1A, CMT1B, and CMTX1. Our study emphasizes a relative oligogenic basis in childhood-onset demyelinating CMT and atypical findings may be observed especially in MPZ, PMP22, and GJB1 gene variants.

11 April 2023 in Sclerosis
Verified
Journal Article
Open access
PDF file
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Igor Braga FariasIgor Braga Farias
Igor Braga Farias
PSPaulo de Lima Serrano
Paulo de Lima Serrano
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
AJAna Carolina dos Santos Jorge
Ana Carolina dos Santos Jorge
Acary Souza Bulle OliveiraAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
A 38-year-old Brazilian man presented with slowly progressive quadriparesis since age 11 years. He progressed over 15 years with symptoms restricted to the lower limbs, and since then, with a progressive compromise of the upper limbs. His deceased brother had a similar clinical presentation. Examination showed spastic dysarthria, global amyotrophy, brisk tendon reflexes in the lower limbs, symmetrical quadriparesis, and fasciculations in the four limbs. Neurophysiological studies disclosed acute and chronic signs of denervation and chronic reinnervation involving the cervical, thoracic, and lumbosacral myotomes, with normal sensory conduction study. Fibrillation potentials, fasciculations, and positive sharp waves involved mainly the upper limbs. A diagnosis of long-standing juvenile-onset motor neuronopathy was established. Genetic testing identified the possibly pathogenic variant c.3G>T (p.Met1?) in homozygosity in the COQ7 gene. This report highlights the importance of considering a potentially treatable metabolic dysfunction as the primary mechanism in cases of juvenile motor neuron disease.

6 February 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
PSPaulo de Lima Serrano
Paulo de Lima Serrano
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
JBJoão Paulo Barile
João Paulo Barile
PMPatrícia Marques Mendes
Patrícia Marques Mendes
RCRenan Brandão Rambaldi Cavalheiro
Renan Brandão Rambaldi Cavalheiro
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Secondary hypertension and resistant hypertension may result from potentially treatable acquired or hereditary diseases. Inherited Metabolic Disorders are not routinely included in the differential diagnosis of these contexts associated with hypertension, despite the key importance of diagnosis for several of them which enable the early treatment of them. We aim to discuss the current evidence that indicates that a significant portion of cases of unknown resistant hypertension or suspected secondary hypertension may result from unrecognized Acute Hepatic Porphyria (AHP). Diagnostic work-up for AHP is not routinely performed during the evaluation of patients with resistant or refractory hypertension nor in the investigation of secondary hypertension. AHP may present both with neurological and systemic involvement, and hypertension may be observed as part of acute dysautonomia during acute neurovisceral attacks and as a chronic complication during disease course. As AHP represent a potentially treatable group of metabolic disorders, clinicians should consider the inclusion of this group in the diagnostic evaluation of patients with secondary or resistant hypertension.

1 December 2012
Verified
Journal Article
Closed access
Roberta Ismael Lacerda MachadoRoberta Ismael Lacerda Machado
Roberta Ismael Lacerda Machado
LSLaís Medeiros Souto
Laís Medeiros Souto
EFEutilia Andrade Medeiros Freire
Eutilia Andrade Medeiros Freire